| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000030060 |
| Receipt No. | R000033294 |
| Official scientific title of the study | Study of proteins modulating gliosis in cerebrospinal fluid in neurodegenerative diseases |
| Date of disclosure of the study information | 2017/11/21 |
| Last modified on | 2018/06/08 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Study of proteins modulating gliosis in cerebrospinal fluid in neurodegenerative diseases | |
| Title of the study (Brief title) | Study of proteins modulating gliosis in neurodegenerative diseases | |
| Region |
|
|
| Condition | ||
| Condition | amyotrophic lateral sclerosis (ALS) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To reveal the changes of proteins modulating gliosis in cerebrospinal fluid (CSF) in neurodegenerative diseases and to develop new biomarkers for neurodegenerative diseases |
| Basic objectives2 | Others |
| Basic objectives -Others | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron death accompanied by excessive gliosis in spinal ventral horn.
Increased astrocytes and microglia in neurodegenerative disease are considered to be harmful to neurons. However, little is known about mechanism of gliosis. We have detected a protein that promotes astrocytosis in CSF of ALS model rats. |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Quantification of gliosis-moderating proteins in CSF from ALS patients using enzyme-linked immunosorbent assay (ELISA) |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Sporadic ALS
ALS patients diagnosed as "clinically probable laboratory supported", "clinically probable" or "clinically definite" with El Escorial revised diagnostic criteria (WFN) 2. SOD1-linked ALS ALS patients with SOD1 mutation 3. Control other neurological diseases |
|||
| Key exclusion criteria | Patients with a history of intrathecal infection
Patients with a history of intrathecal drug administration Patients with a history of spine or spinal cord surgery |
|||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Hitoshi Warita |
| Organization | Tohoku University Hospital |
| Division name | Department of Neurology |
| Address | Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, Japan |
| TEL | 022-717-7189 |
| warita-ns@umin.net | |
| Public contact | |
| Name of contact person | Tomomi Shijo |
| Organization | Tohoku University Graduate School of Medicine |
| Division name | Department of Neurology |
| Address | Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, Japan |
| TEL | 022-717-7189 |
| Homepage URL | |
| shijo-t@med.tohoku.ac.jp | |
| Sponsor | |
| Institute | Tohoku University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ministry of Education, Culture, Sports, Science and Technology |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | a |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000033294 |